Table 2.
Results from the clinical assessment of current and backdated lists from Tunisia, Brazil and Indonesia of drug–event combinations reported disproportionately often
| Combination list | No. of reports | No. of DECs with IC025 > 0 | No. of labelled/known DECs | |
|---|---|---|---|---|
| Yes | No (with/without explanation) | |||
| Tunisia currenta | 7189 | 201 | 191 (95%) | 10 (0/10) |
| Tunisia 2010 | 4209 | 100 | 99 (99%) | 1 (0/1) |
| Tunisia 2000 | 634 | 10 | 9 (90%) | 1 (0/1) |
| Brazil currenta | 6064 | 479 | 423 (88%) | 56 (39/17) |
| Brazil 2015 | 4297 | 315 | 273 (87%) | 42 (30/12) |
| Brazil 2002 | 932 | 29 | 29 (100%) | 0 (0/0) |
| Indonesia currenta | 6925 | 389 | 368 (95%) | 21 (1/20) |
| Indonesia 2013 | 4156 | 191 | 189 (99%) | 2 (0/2) |
| Indonesia 1976b | 564 | 21 | 20 (95%) | 1 (0/1) |
DEC drug–event combination, IC information component
aAs of the end of the data extract (i.e. 2 January 2018)
bThis is data collected prior to Indonesia joining the WHO Programme for International Drug Monitoring in 1990, which has been retroactively added to VigiBase